Is Octinoxate safe in cosmetics?
Octinoxate has a safety rating of "MODERATE" in our database. EU status: permitted. US status: restricted. 10 toxicological study endpoint(s) are available in our database. This ingredient has been reviewed by sccs.
Also known as: 2-Ethylhexyl 3-(4-methoxyphenyl)prop-2-enoate, 2-Ethylhexyl-4-methoxycinnamate, Ethylhexyl p-methoxycinnamate, 2-Propenoic acid, 3-(4-methoxyphenyl)-, 2-ethylhexyl ester, Octyl methoxycinnamate (+2 more)
INCI: ETHYLHEXYL METHOXYCINNAMATE
Octinoxate (CAS 5466-77-3) is a cosmetic active ingredient functioning as Oil-soluble UVB UV filter; peak absorption ~311 nm; undergoes trans-to-cis. NOAEL 450 mg/kg bw/day (PDF-verified against ToxValDB ECHA IUCLID); EU Regulation 1223/2009 status: permitted, max 10%; 5 safety opinions reviewed (sccs). Industrial safety data is also available in the chemical safety database. Same-CAS public records also appear in pharmaceutical data.
View industrial chemical safety profile for CAS 5466-77-3 →
For full compliance data across multiple jurisdictions, use the Substance Compliance tool.
Margin of Safety, dermal absorption, and sensitization profile summaries for Octinoxate.
Calculate MoS for your specific formulation with the MoS Calculator.
10 study endpoints found for Octinoxate. NOAEL (No Observed Adverse Effect Level) values are used to calculate the Margin of Safety per SCCS methodology.
| Endpoint | Value | Route | Species | Study Type | Source |
|---|---|---|---|---|---|
| NOAEL | =100 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =100 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =100 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =100 mg/kg bw/day | oral | rat | NOAEL study | SCCS_vision_codex |
| NOAEL | =450 mg/kg bw/day | - | - | NOAEL study | SCCS_vision_codex |
| NOAEL | =450 mg/kg bw/day | - | - | NOAEL study | SCCS_vision_codex |
| NOAEL | =450 mg/kg bw/day | - | - | NOAEL study | SCCS_vision_codex |
| NOAEL | =450 mg/kg bw/day | - | - | NOAEL study | SCCS_vision_codex |
| NOAEL | =500 mg/kg bw/day | - | - | reproductive toxicity | SCCS_vision_codex |
| NOAEL | =500 mg/kg bw/day | - | - | reproductive toxicity | SCCS_vision_codex |
Official safety assessments from the Scientific Committee on Consumer Safety (SCCS) and Cosmetic Ingredient Review (CIR).
otential endocrine disrupting properties of EHMC, the SCCS is of the opinion that EHMC is safe when used as a UV filter up to a maximum concentration of 10% in sunscreen lotion, face and hand cream, lipstick, sunscreen propellant spray and pump spray, when used separately or in combination.
otential endocrine disrupting properties of EHMC, the SCCS is of the opinion that EHMC is safe when used as a UV filter up to a maximum concentration of 10% in sunscreen lotion, face and hand cream, lipstick, sunscreen propellant spray and pump spray, when used separately or in combination.
otential endocrine disrupting properties of EHMC, the SCCS is of the opinion that EHMC is safe when used as a UV filter up to a maximum concentration of 10% in sunscreen lotion, face and hand cream, lipstick, sunscreen propellant spray and pump spray, when used separately or in combination.
otential endocrine disrupting properties of EHMC, the SCCS is of the opinion that EHMC is safe when used as a UV filter up to a maximum concentration of 10% in sunscreen lotion, face and hand cream, lipstick, sunscreen propellant spray and pump spray, when used separately or in combination.
otential endocrine disrupting properties of EHMC, the SCCS is of the opinion that EHMC is safe when used as a UV filter up to a maximum concentration of 10% in sunscreen lotion, face and hand cream, lipstick, sunscreen propellant spray and pump spray, when used separately or in combination.
Pre-calculated NOAEL → SED → MoS audit trail for Octinoxate across SCCS product categories, with measured dermal absorption where available.
Adverse Outcome Pathway data across 5 assays (DPRA, KeratinoSens, hCLAT, LLNA, NESIL) aggregated from public sources.
Source: DPRA: Cosmetics Europe; KS: Cosmetics Europe; hCLAT: Cosmetics Europe
Cross-referenced EDC classifications, mechanism data, and dose-response evidence from EDLists, SIN List, and cosmetic-specific detail sources.
antagonist (ER, AR, TR, PR)
| Endpoint | Target | Value | Direction |
|---|---|---|---|
| dermal_RF_16h | skin | 0.03 ± 0.07 µg/cm² | - |
| dermal_systemic | skin | 0.002% % | - |
| plasma_conc | systemic | 10–20 ng/mL ng/mL | - |
| Cell proliferation | ER | EC50/IC50: ~1.6 uM; LOEC: 0.3 uM; NOEC: 0.1 uM mixed | agonist |
| Luciferase ERE transcriptional activation | ER | EC50/IC50: ~0.5-1 uM (ERa); LOEC: 0.1 uM; NOEC: 0.01 uM mixed | agonist |
European Commission CosIng database Annex references per Regulation (EC) No 1223/2009.
Additional regulatory detail beyond the 7-jurisdiction summary: Saudi SFDA, Korea MFDS, ASEAN ACD, Japan/Korea, Brazil/India, and cross-jurisdictional restriction entries.
| Jurisdiction | Status | Max % | Product Type |
|---|---|---|---|
| JP | restricted | Wash-away: 20% | Leave-on: 20% | Mucosa: 8.0% | Wash-away: 20% | Leave-on: 20% | Mucosa: 8.0% |
| CN | permitted_uv_filter | 10 | All cosmetics |
| IN | permitted_uv_filter | 10.0 | sunscreen and other cosmetic products |
| AU | restricted | - | sunscreens (therapeutic) |
| BR | permitted_uv_filter | 10 | Sunscreen products |
| ASEAN | permitted_uv_filter | 10% | - |
Cross-database dermal penetration: EPA Dryad physics-based, Roberts Mendeley permeation, and SCCS-aggregated measured values.
| Type | DA % | Method | Skin Model | SCCS Ref |
|---|---|---|---|---|
| measured_in_vitro | 1.5 | In vivo — human volunteers (plasma/urine monitoring) | - | SCC 1996; SCCS 2025 (EHMC) (1996) |
Reported concentration ranges per product category from SCCS/CIR/industry sources.
| Product Category | Typical Range | Max Reported | Source |
|---|---|---|---|
| Sunscreen | 3–7.5 | 7.5 | CIR/FDA OTC |
| Foundation | 1–3 | 7.5 | CIR/VCRP |
3 property records from structured ingredient metadata.
Expert safety assessment and concern-level summary for Octinoxate.
Public NOAEL study rows linked to Octinoxate by CAS number or substance name.
| Absorption % | Method | Vehicle |
|---|---|---|
| 1.5 | In vivo — human volunteers (plasma/urine monitoring) | o/w sunscreen formulation |
Same-CAS public records found in pharmaceutical data.
Same-CAS rows from the pharmaceutical spoke database.
Octinoxate has a safety rating of "MODERATE" in our database. EU status: permitted. US status: restricted. 10 toxicological study endpoint(s) are available in our database. This ingredient has been reviewed by sccs.
Octinoxate EU regulatory status: permitted. Maximum allowed concentration: 10%. This is based on EU Regulation 1223/2009 and its amendments.
Octinoxate functions as: Oil-soluble UVB UV filter; peak absorption ~311 nm; undergoes trans-to-cis photoisomerization under UV exposure causing progressive SPF loss. It is classified as a Active Ingredient in our database. CAS number: 5466-77-3.
The NOAEL (No Observed Adverse Effect Level) for Octinoxate is =100 mg/kg bw/day based on a NOAEL study study via oral route in rat. A total of 10 study endpoints are available. Source: SCCS_vision_codex.
Octinoxate also appears in pharmaceutical data. The cross-vertical cards on this page render same-CAS public rows from the matched databases.
Check Octinoxate compliance across multiple jurisdictions:
Scan any product label with Piro — our free ingredient scanner. Point your camera at the ingredients list and get instant safety scores for every ingredient.
Try Piro Free →Paste any INCI list into the Decoder for instant safety analysis, or calculate the Margin of Safety for Octinoxate in your formulation.